Noor Ul Ain Rehman
Tue, March 31, 2026 astatine 10:06 AM CDT 2 min read
BioNTech SE (NASDAQ:BNTX) besides received a standing update from Morgan Stanley connected March 11. The steadfast chopped the terms people connected the banal to $125 from $134 and maintained an Overweight standing connected the shares, telling investors that the institution amazingly announced a enactment modulation successful conjunction with its Q4 report. This overshadowed the fiscal Q4 results and the archetypal 2026 guidance. However, the steadfast added that it sees shares arsenic undervalued up of a fig of information read-outs pursuing the selloff successful the stock.
BioNTech SE (NASDAQ:BNTX) is simply a German biotechnology institution that creates messenger RNA (mRNA) therapeutics and vaccines to code superior diseases specified arsenic crab and infectious diseases. It specializes successful processing and manufacturing immunotherapies for patient-specific approaches.
While we admit the imaginable of BNTX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich successful 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey connected Google News.

2 days ago
3



.png)

English (CA) ·
English (US) ·
Spanish (MX) ·